| Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes MC Petrie, S Verma, KF Docherty, SE Inzucchi, I Anand, J Bělohlávek, ... Jama 323 (14), 1353-1368, 2020 | 486 | 2020 |
| Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis KM Hallow, G Helmlinger, PJ Greasley, JJV McMurray, DW Boulton Diabetes, Obesity and Metabolism 20 (3), 479-487, 2018 | 485 | 2018 |
| Dapagliflozin, a novel SGLT2 inhibitor, induces dose‐dependent glucosuria in healthy subjects B Komoroski, N Vachharajani, D Boulton, D Kornhauser, M Geraldes, L Li, ... Clinical Pharmacology & Therapeutics 85 (5), 520-526, 2009 | 457 | 2009 |
| Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes RA DeFronzo, M Hompesch, S Kasichayanula, X Liu, Y Hong, M Pfister, ... Diabetes care 36 (10), 3169-3176, 2013 | 353 | 2013 |
| In vitro P-glycoprotein affinity for atypical and conventional antipsychotics DW Boulton, CL DeVane, HL Liston, JS Markowitz Life sciences 71 (2), 163-169, 2002 | 317 | 2002 |
| Extensive binding of the bioflavonoid quercetin to human plasma proteins DW Boulton, UK Walle, T Walle Journal of Pharmacy and Pharmacology 50 (2), 243-249, 1998 | 267 | 1998 |
| Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2 S Kasichayanula, X Liu, F LaCreta, SC Griffen, DW Boulton Clinical pharmacokinetics 53, 17-27, 2014 | 249 | 2014 |
| Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers JS Markowitz, CL DeVane, DW Boulton, SW Carson, Z Nahas, SC Risch Life sciences 66 (9), PL133-PL139, 2000 | 219 | 2000 |
| Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF AM Jackson, P Dewan, IS Anand, J Bělohlávek, O Bengtsson, RA de Boer, ... Circulation 142 (11), 1040-1054, 2020 | 166 | 2020 |
| Fate of the flavonoid quercetin in human cell lines: chemical instability and metabolism DW Boulton, UK Walle, T Walle Journal of pharmacy and pharmacology 51 (3), 353-359, 1999 | 161 | 1999 |
| Interaction between the sodium‐glucose–linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects CS Wilcox, W Shen, DW Boulton, BR Leslie, SC Griffen Journal of the American Heart Association 7 (4), e007046, 2018 | 147 | 2018 |
| The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus S Kasichayanula, X Liu, M Pe Benito, M Yao, M Pfister, FP LaCreta, ... British journal of clinical pharmacology 76 (3), 432-444, 2013 | 137 | 2013 |
| Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections A Fura, A Khanna, V Vyas, B Koplowitz, SY Chang, C Caporuscio, ... Drug metabolism and disposition 37 (6), 1164-1171, 2009 | 137 | 2009 |
| Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium–glucose co‐transporter type 2, in Japanese subjects without and with type 2 … S Kasichayanula, M Chang, M Hasegawa, X Liu, N Yamahira, FP LaCreta, ... Diabetes, Obesity and Metabolism 13 (4), 357-365, 2011 | 128 | 2011 |
| Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin D Boulton, L Li, EU Frevert, A Tang, L Castaneda, NN Vachharajani, ... Clinical pharmacokinetics 50, 253-265, 2011 | 125 | 2011 |
| Enantioselective disposition of salbutamol in man following oral and intravenous administration DW Boulton, JP Fawcett British journal of clinical pharmacology 41 (1), 35-40, 1996 | 124 | 1996 |
| Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol JS Markowitz, CL DeVane, DW Boulton, Z Nahas, SC Risch, F Diamond, ... Drug Metabolism and Disposition 28 (6), 620-624, 2000 | 117 | 2000 |
| Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium–glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy … S Kasichayanula, X Liu, WC Shyu, W Zhang, M Pfister, SC Griffen, T Li, ... Diabetes, Obesity and Metabolism 13 (1), 47-54, 2011 | 108 | 2011 |
| Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study S Kasichayanula, X Liu, W Zhang, M Pfister, FP LaCreta, DW Boulton Clinical therapeutics 33 (11), 1798-1808, 2011 | 103 | 2011 |
| Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes CCJ Dekkers, CD Sjöström, PJ Greasley, V Cain, DW Boulton, ... Diabetes, Obesity and Metabolism 21 (12), 2667-2673, 2019 | 100 | 2019 |
